Paragraph 25 F1

A list of information which is necessary before the medicinal product is taken or used, including—

(a)

contra-indications;

(b)

appropriate precautions for use;

(c)

interactions with other medicinal products which may affect the action of the product;

(d)

interactions with other substances, including alcohol, tobacco and foodstuffs which may affect the action of the product;

(e)

special warnings; if any, relating to the product.

Annotations

F1: Sch. 27 Pt. 3 inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 204(6) (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 158(e)); 2020 c. 1, Sch. 5 para. 1(1)

F2: Words in Sch. 27 Pt. 3 heading omitted (1.1.2025) by virtue of The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024 (S.I. 2024/832), regs. 1(1), 143(c)